Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia Article Swipe
Alessandro Broccoli
,
Lisa Argnani
,
Laura Nanni
,
Ginevra Lolli
,
Vittorio Stefoni
,
Stefano Zoli
,
Mariateresa Cantelli
,
Cinzia Pellegrini
,
Alice Morigi
,
Marianna Gentilini
,
Emanuele Sutto
,
Gabriele Gugliotta
,
Paolo Elia Coppola
,
Beatrice Casadei
,
Matteo Carella
,
Gianmarco Bagnato
,
Pier Luigi Zinzani
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1002/hon.3164_289
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1002/hon.3164_289
Introduction: Hairy cell leukemia (HCL) patients usually experience multiple disease relapses during the course of their disease. The CD20 antigen is highly expressed on the surface of hairy cells. Single-agent rituximab can be a suitable treatment options in patients relapsing after repeated courses of purine analogs, if purine analogs are contraindicated (e.g., in case of poor bone marrow cellularity, high disease infiltration predicting long-lasting aplasia), especially if newer agents (such as moxetumomab or vemurafenib) are not easily available (as it happens in several countries). Methods: Our institutional series of HCL patients receiving single-agent rituximab as salvage therapy was retrospectively reviewed. Patients received rituximab at the standard dose of 375 mg/m2 weekly for 4 weeks. The main study objectives were overall response rate (ORR), time-to-next treatment (TTNT), progression-free survival (PFS) and overall survival (OS). Responses have been categorized according to the Consensus Resolution Criteria. Results: Thirty-three patients received 39 courses of rituximab (4 patients received it twice, one patient three times), in median as third line of therapy (range 2–8). First rituximab was given at a median age of 61 years and at a median time from disease diagnosis of 65 months. Out of 39 courses, a complete response was obtained in 28.2% of cases, a partial response in 23.1% and a minimal response in 20.5%, yielding an ORR of 71.8%. In 28.2% of patients, we observed no response. Median TTNT was reached at 33 months (65% at 2 years), while median PFS was reached at 24 months (51% at 2 years). Median OS resulted of 154 months (22% at 20 years). Among the 5 patients receiving rituximab more than once, all responded after the first course, although the ORR after the second or later course was only 50%. Median TTNT following the first rituximab was 38.5 months in these patients, ranging from 15 to 205 months. Keywords: Immunotherapy, Lymphoid Cancers No conflicts of interests pertinent to the abstract.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/hon.3164_289
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4379981784
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4379981784Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/hon.3164_289Digital Object Identifier
- Title
-
Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemiaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-06-01Full publication date if available
- Authors
-
Alessandro Broccoli, Lisa Argnani, Laura Nanni, Ginevra Lolli, Vittorio Stefoni, Stefano Zoli, Mariateresa Cantelli, Cinzia Pellegrini, Alice Morigi, Marianna Gentilini, Emanuele Sutto, Gabriele Gugliotta, Paolo Elia Coppola, Beatrice Casadei, Matteo Carella, Gianmarco Bagnato, Pier Luigi ZinzaniList of authors in order
- Landing page
-
https://doi.org/10.1002/hon.3164_289Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289Direct OA link when available
- Concepts
-
Medicine, Rituximab, Salvage therapy, Purine analogue, Internal medicine, Surgery, Gastroenterology, Oncology, Chemotherapy, Lymphoma, Purine, Chemistry, Enzyme, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4379981784 |
|---|---|
| doi | https://doi.org/10.1002/hon.3164_289 |
| ids.doi | https://doi.org/10.1002/hon.3164_289 |
| ids.openalex | https://openalex.org/W4379981784 |
| fwci | 0.0 |
| type | article |
| title | Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia |
| biblio.issue | S2 |
| biblio.volume | 41 |
| biblio.last_page | 397 |
| biblio.first_page | 397 |
| topics[0].id | https://openalex.org/T11157 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2716 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Chronic Lymphocytic Leukemia Research |
| topics[1].id | https://openalex.org/T11725 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9973999857902527 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunodeficiency and Autoimmune Disorders |
| topics[2].id | https://openalex.org/T11016 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9902999997138977 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2741 |
| topics[2].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[2].display_name | Monoclonal and Polyclonal Antibodies Research |
| is_xpac | False |
| apc_list.value | 4220 |
| apc_list.currency | USD |
| apc_list.value_usd | 4220 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9054629802703857 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2780653079 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8953084349632263 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[1].display_name | Rituximab |
| concepts[2].id | https://openalex.org/C2780775027 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6287544965744019 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q17141389 |
| concepts[2].display_name | Salvage therapy |
| concepts[3].id | https://openalex.org/C109246011 |
| concepts[3].level | 4 |
| concepts[3].score | 0.5622865557670593 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q6593447 |
| concepts[3].display_name | Purine analogue |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5487627387046814 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C141071460 |
| concepts[5].level | 1 |
| concepts[5].score | 0.48172691464424133 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[5].display_name | Surgery |
| concepts[6].id | https://openalex.org/C90924648 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4386731684207916 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[6].display_name | Gastroenterology |
| concepts[7].id | https://openalex.org/C143998085 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3869476020336151 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[7].display_name | Oncology |
| concepts[8].id | https://openalex.org/C2776694085 |
| concepts[8].level | 2 |
| concepts[8].score | 0.2897006869316101 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[8].display_name | Chemotherapy |
| concepts[9].id | https://openalex.org/C2779338263 |
| concepts[9].level | 2 |
| concepts[9].score | 0.17422401905059814 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[9].display_name | Lymphoma |
| concepts[10].id | https://openalex.org/C2776476023 |
| concepts[10].level | 3 |
| concepts[10].score | 0.11721676588058472 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q188261 |
| concepts[10].display_name | Purine |
| concepts[11].id | https://openalex.org/C185592680 |
| concepts[11].level | 0 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[11].display_name | Chemistry |
| concepts[12].id | https://openalex.org/C181199279 |
| concepts[12].level | 2 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q8047 |
| concepts[12].display_name | Enzyme |
| concepts[13].id | https://openalex.org/C55493867 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[13].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9054629802703857 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/rituximab |
| keywords[1].score | 0.8953084349632263 |
| keywords[1].display_name | Rituximab |
| keywords[2].id | https://openalex.org/keywords/salvage-therapy |
| keywords[2].score | 0.6287544965744019 |
| keywords[2].display_name | Salvage therapy |
| keywords[3].id | https://openalex.org/keywords/purine-analogue |
| keywords[3].score | 0.5622865557670593 |
| keywords[3].display_name | Purine analogue |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5487627387046814 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/surgery |
| keywords[5].score | 0.48172691464424133 |
| keywords[5].display_name | Surgery |
| keywords[6].id | https://openalex.org/keywords/gastroenterology |
| keywords[6].score | 0.4386731684207916 |
| keywords[6].display_name | Gastroenterology |
| keywords[7].id | https://openalex.org/keywords/oncology |
| keywords[7].score | 0.3869476020336151 |
| keywords[7].display_name | Oncology |
| keywords[8].id | https://openalex.org/keywords/chemotherapy |
| keywords[8].score | 0.2897006869316101 |
| keywords[8].display_name | Chemotherapy |
| keywords[9].id | https://openalex.org/keywords/lymphoma |
| keywords[9].score | 0.17422401905059814 |
| keywords[9].display_name | Lymphoma |
| keywords[10].id | https://openalex.org/keywords/purine |
| keywords[10].score | 0.11721676588058472 |
| keywords[10].display_name | Purine |
| language | en |
| locations[0].id | doi:10.1002/hon.3164_289 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S23714410 |
| locations[0].source.issn | 0278-0232, 1099-1069 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0278-0232 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Hematological Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Hematological Oncology |
| locations[0].landing_page_url | https://doi.org/10.1002/hon.3164_289 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5090561717 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5633-7313 |
| authorships[0].author.display_name | Alessandro Broccoli |
| authorships[0].countries | IT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[0].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I9360294 |
| authorships[0].affiliations[1].raw_affiliation_string | Department of Medical and Surgical sciences (DIMEC), University of Bologna, Bologna, Italy |
| authorships[0].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[0].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[0].institutions[0].country_code | IT |
| authorships[0].institutions[0].display_name | Azienda USL di Bologna |
| authorships[0].institutions[1].id | https://openalex.org/I9360294 |
| authorships[0].institutions[1].ror | https://ror.org/01111rn36 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I9360294 |
| authorships[0].institutions[1].country_code | IT |
| authorships[0].institutions[1].display_name | University of Bologna |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | A. Broccoli |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Medical and Surgical sciences (DIMEC), University of Bologna, Bologna, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[1].author.id | https://openalex.org/A5044832096 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4225-4626 |
| authorships[1].author.display_name | Lisa Argnani |
| authorships[1].countries | IT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[1].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[1].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[1].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[1].institutions[0].country_code | IT |
| authorships[1].institutions[0].display_name | Azienda USL di Bologna |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | L. Argnani |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[2].author.id | https://openalex.org/A5107946903 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Laura Nanni |
| authorships[2].countries | IT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[2].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[2].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[2].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[2].institutions[0].country_code | IT |
| authorships[2].institutions[0].display_name | Azienda USL di Bologna |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | L. Nanni |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[3].author.id | https://openalex.org/A5112657917 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Ginevra Lolli |
| authorships[3].countries | IT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[3].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[3].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[3].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[3].institutions[0].country_code | IT |
| authorships[3].institutions[0].display_name | Azienda USL di Bologna |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | G. Lolli |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[4].author.id | https://openalex.org/A5039739851 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Vittorio Stefoni |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[4].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[4].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[4].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | Azienda USL di Bologna |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | V. Stefoni |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[5].author.id | https://openalex.org/A5067392007 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-0385-914X |
| authorships[5].author.display_name | Stefano Zoli |
| authorships[5].countries | IT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[5].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[5].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[5].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[5].institutions[0].country_code | IT |
| authorships[5].institutions[0].display_name | Azienda USL di Bologna |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | S. Zoli |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[6].author.id | https://openalex.org/A5079184402 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-4429-3741 |
| authorships[6].author.display_name | Mariateresa Cantelli |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[6].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[6].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | Azienda USL di Bologna |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M. Cantelli |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[7].author.id | https://openalex.org/A5046793649 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-5223-4429 |
| authorships[7].author.display_name | Cinzia Pellegrini |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210117483 |
| authorships[7].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[7].institutions[0].id | https://openalex.org/I4210117483 |
| authorships[7].institutions[0].ror | https://ror.org/01mze9517 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210117483 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | Istituto di Ematologia di Bologna |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | C. Pellegrini |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[8].author.id | https://openalex.org/A5111328092 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Alice Morigi |
| authorships[8].countries | IT |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[8].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[8].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[8].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[8].institutions[0].country_code | IT |
| authorships[8].institutions[0].display_name | Azienda USL di Bologna |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | A. Morigi |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[9].author.id | https://openalex.org/A5009278646 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Marianna Gentilini |
| authorships[9].countries | IT |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[9].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[9].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[9].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[9].institutions[0].country_code | IT |
| authorships[9].institutions[0].display_name | Azienda USL di Bologna |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | M. Gentilini |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[10].author.id | https://openalex.org/A5056113233 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Emanuele Sutto |
| authorships[10].countries | IT |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[10].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[10].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[10].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[10].institutions[0].country_code | IT |
| authorships[10].institutions[0].display_name | Azienda USL di Bologna |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | E. Sutto |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[11].author.id | https://openalex.org/A5035566807 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Gabriele Gugliotta |
| authorships[11].countries | IT |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210117483 |
| authorships[11].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[11].institutions[0].id | https://openalex.org/I4210117483 |
| authorships[11].institutions[0].ror | https://ror.org/01mze9517 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210117483 |
| authorships[11].institutions[0].country_code | IT |
| authorships[11].institutions[0].display_name | Istituto di Ematologia di Bologna |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | G. Gugliotta |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[12].author.id | https://openalex.org/A5112933410 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Paolo Elia Coppola |
| authorships[12].countries | IT |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[12].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[12].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[12].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[12].institutions[0].country_code | IT |
| authorships[12].institutions[0].display_name | Azienda USL di Bologna |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | P. E. Coppola |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[13].author.id | https://openalex.org/A5070351821 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-4453-6064 |
| authorships[13].author.display_name | Beatrice Casadei |
| authorships[13].countries | IT |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210117483 |
| authorships[13].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[13].institutions[0].id | https://openalex.org/I4210117483 |
| authorships[13].institutions[0].ror | https://ror.org/01mze9517 |
| authorships[13].institutions[0].type | facility |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210117483 |
| authorships[13].institutions[0].country_code | IT |
| authorships[13].institutions[0].display_name | Istituto di Ematologia di Bologna |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | B. Casadei |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy |
| authorships[14].author.id | https://openalex.org/A5065207434 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-5997-6452 |
| authorships[14].author.display_name | Matteo Carella |
| authorships[14].countries | IT |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[14].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[14].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[14].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[14].institutions[0].country_code | IT |
| authorships[14].institutions[0].display_name | Azienda USL di Bologna |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | M. Carella |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[15].author.id | https://openalex.org/A5036474711 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Gianmarco Bagnato |
| authorships[15].countries | IT |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[15].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[15].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[15].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[15].institutions[0].country_code | IT |
| authorships[15].institutions[0].display_name | Azienda USL di Bologna |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | G. Bagnato |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[16].author.id | https://openalex.org/A5091882595 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-2112-2651 |
| authorships[16].author.display_name | Pier Luigi Zinzani |
| authorships[16].countries | IT |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210119117 |
| authorships[16].affiliations[0].raw_affiliation_string | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| authorships[16].institutions[0].id | https://openalex.org/I4210119117 |
| authorships[16].institutions[0].ror | https://ror.org/02mby1820 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210119117 |
| authorships[16].institutions[0].country_code | IT |
| authorships[16].institutions[0].display_name | Azienda USL di Bologna |
| authorships[16].author_position | last |
| authorships[16].raw_author_name | P. L. Zinzani |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11157 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2716 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Chronic Lymphocytic Leukemia Research |
| related_works | https://openalex.org/W2411583971, https://openalex.org/W2781286807, https://openalex.org/W31297289, https://openalex.org/W3082504439, https://openalex.org/W2265981062, https://openalex.org/W4251119054, https://openalex.org/W2060135514, https://openalex.org/W2033218397, https://openalex.org/W2024961110, https://openalex.org/W2284624791 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1002/hon.3164_289 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S23714410 |
| best_oa_location.source.issn | 0278-0232, 1099-1069 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0278-0232 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Hematological Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Hematological Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1002/hon.3164_289 |
| primary_location.id | doi:10.1002/hon.3164_289 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S23714410 |
| primary_location.source.issn | 0278-0232, 1099-1069 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0278-0232 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Hematological Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_289 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Hematological Oncology |
| primary_location.landing_page_url | https://doi.org/10.1002/hon.3164_289 |
| publication_date | 2023-06-01 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 237, 249 |
| abstract_inverted_index.4 | 112 |
| abstract_inverted_index.5 | 263 |
| abstract_inverted_index.a | 33, 174, 182, 195, 204, 210 |
| abstract_inverted_index.(4 | 151 |
| abstract_inverted_index.15 | 302 |
| abstract_inverted_index.20 | 259 |
| abstract_inverted_index.24 | 245 |
| abstract_inverted_index.33 | 233 |
| abstract_inverted_index.39 | 147, 193 |
| abstract_inverted_index.61 | 178 |
| abstract_inverted_index.65 | 189 |
| abstract_inverted_index.In | 220 |
| abstract_inverted_index.No | 310 |
| abstract_inverted_index.OS | 252 |
| abstract_inverted_index.an | 216 |
| abstract_inverted_index.as | 70, 94, 162 |
| abstract_inverted_index.at | 103, 173, 181, 232, 236, 244, 248, 258 |
| abstract_inverted_index.be | 32 |
| abstract_inverted_index.if | 46, 66 |
| abstract_inverted_index.in | 37, 52, 81, 160, 200, 207, 213, 297 |
| abstract_inverted_index.is | 20 |
| abstract_inverted_index.it | 79, 154 |
| abstract_inverted_index.no | 226 |
| abstract_inverted_index.of | 14, 26, 43, 54, 88, 107, 149, 165, 177, 188, 192, 202, 218, 222, 254, 312 |
| abstract_inverted_index.on | 23 |
| abstract_inverted_index.or | 72, 282 |
| abstract_inverted_index.to | 138, 303, 315 |
| abstract_inverted_index.we | 224 |
| abstract_inverted_index.(as | 78 |
| abstract_inverted_index.154 | 255 |
| abstract_inverted_index.205 | 304 |
| abstract_inverted_index.375 | 108 |
| abstract_inverted_index.HCL | 89 |
| abstract_inverted_index.ORR | 217, 278 |
| abstract_inverted_index.Our | 85 |
| abstract_inverted_index.Out | 191 |
| abstract_inverted_index.PFS | 241 |
| abstract_inverted_index.The | 17, 114 |
| abstract_inverted_index.age | 176 |
| abstract_inverted_index.all | 270 |
| abstract_inverted_index.and | 129, 180, 209 |
| abstract_inverted_index.are | 49, 74 |
| abstract_inverted_index.can | 31 |
| abstract_inverted_index.for | 111 |
| abstract_inverted_index.not | 75 |
| abstract_inverted_index.one | 156 |
| abstract_inverted_index.the | 12, 24, 104, 139, 262, 273, 277, 280, 291, 316 |
| abstract_inverted_index.was | 97, 171, 198, 230, 242, 285, 294 |
| abstract_inverted_index.(22% | 257 |
| abstract_inverted_index.(51% | 247 |
| abstract_inverted_index.(65% | 235 |
| abstract_inverted_index.38.5 | 295 |
| abstract_inverted_index.50%. | 287 |
| abstract_inverted_index.CD20 | 18 |
| abstract_inverted_index.TTNT | 229, 289 |
| abstract_inverted_index.been | 135 |
| abstract_inverted_index.bone | 56 |
| abstract_inverted_index.case | 53 |
| abstract_inverted_index.cell | 2 |
| abstract_inverted_index.dose | 106 |
| abstract_inverted_index.from | 185, 301 |
| abstract_inverted_index.have | 134 |
| abstract_inverted_index.high | 59 |
| abstract_inverted_index.line | 164 |
| abstract_inverted_index.main | 115 |
| abstract_inverted_index.more | 267 |
| abstract_inverted_index.only | 286 |
| abstract_inverted_index.poor | 55 |
| abstract_inverted_index.rate | 121 |
| abstract_inverted_index.than | 268 |
| abstract_inverted_index.time | 184 |
| abstract_inverted_index.were | 118 |
| abstract_inverted_index.(HCL) | 4 |
| abstract_inverted_index.(OS). | 132 |
| abstract_inverted_index.(PFS) | 128 |
| abstract_inverted_index.(such | 69 |
| abstract_inverted_index.23.1% | 208 |
| abstract_inverted_index.28.2% | 201, 221 |
| abstract_inverted_index.Among | 261 |
| abstract_inverted_index.First | 169 |
| abstract_inverted_index.Hairy | 1 |
| abstract_inverted_index.after | 40, 272, 279 |
| abstract_inverted_index.first | 274, 292 |
| abstract_inverted_index.given | 172 |
| abstract_inverted_index.hairy | 27 |
| abstract_inverted_index.later | 283 |
| abstract_inverted_index.mg/m2 | 109 |
| abstract_inverted_index.newer | 67 |
| abstract_inverted_index.once, | 269 |
| abstract_inverted_index.study | 116 |
| abstract_inverted_index.their | 15 |
| abstract_inverted_index.these | 298 |
| abstract_inverted_index.third | 163 |
| abstract_inverted_index.three | 158 |
| abstract_inverted_index.while | 239 |
| abstract_inverted_index.years | 179 |
| abstract_inverted_index.(ORR), | 122 |
| abstract_inverted_index.(e.g., | 51 |
| abstract_inverted_index.(range | 167 |
| abstract_inverted_index.20.5%, | 214 |
| abstract_inverted_index.71.8%. | 219 |
| abstract_inverted_index.Median | 228, 251, 288 |
| abstract_inverted_index.agents | 68 |
| abstract_inverted_index.cases, | 203 |
| abstract_inverted_index.cells. | 28 |
| abstract_inverted_index.course | 13, 284 |
| abstract_inverted_index.during | 11 |
| abstract_inverted_index.easily | 76 |
| abstract_inverted_index.highly | 21 |
| abstract_inverted_index.marrow | 57 |
| abstract_inverted_index.median | 161, 175, 183, 240 |
| abstract_inverted_index.months | 234, 246, 256, 296 |
| abstract_inverted_index.purine | 44, 47 |
| abstract_inverted_index.second | 281 |
| abstract_inverted_index.series | 87 |
| abstract_inverted_index.twice, | 155 |
| abstract_inverted_index.weekly | 110 |
| abstract_inverted_index.weeks. | 113 |
| abstract_inverted_index.(TTNT), | 125 |
| abstract_inverted_index.2–8). | 168 |
| abstract_inverted_index.Cancers | 309 |
| abstract_inverted_index.analogs | 48 |
| abstract_inverted_index.antigen | 19 |
| abstract_inverted_index.course, | 275 |
| abstract_inverted_index.courses | 42, 148 |
| abstract_inverted_index.disease | 9, 60, 186 |
| abstract_inverted_index.happens | 80 |
| abstract_inverted_index.minimal | 211 |
| abstract_inverted_index.months. | 190, 305 |
| abstract_inverted_index.options | 36 |
| abstract_inverted_index.overall | 119, 130 |
| abstract_inverted_index.partial | 205 |
| abstract_inverted_index.patient | 157 |
| abstract_inverted_index.ranging | 300 |
| abstract_inverted_index.reached | 231, 243 |
| abstract_inverted_index.salvage | 95 |
| abstract_inverted_index.several | 82 |
| abstract_inverted_index.surface | 25 |
| abstract_inverted_index.therapy | 96, 166 |
| abstract_inverted_index.times), | 159 |
| abstract_inverted_index.usually | 6 |
| abstract_inverted_index.years), | 238 |
| abstract_inverted_index.years). | 250, 260 |
| abstract_inverted_index.Lymphoid | 308 |
| abstract_inverted_index.Methods: | 84 |
| abstract_inverted_index.Patients | 100 |
| abstract_inverted_index.Results: | 143 |
| abstract_inverted_index.although | 276 |
| abstract_inverted_index.analogs, | 45 |
| abstract_inverted_index.complete | 196 |
| abstract_inverted_index.courses, | 194 |
| abstract_inverted_index.disease. | 16 |
| abstract_inverted_index.leukemia | 3 |
| abstract_inverted_index.multiple | 8 |
| abstract_inverted_index.observed | 225 |
| abstract_inverted_index.obtained | 199 |
| abstract_inverted_index.patients | 5, 38, 90, 145, 152, 264 |
| abstract_inverted_index.received | 101, 146, 153 |
| abstract_inverted_index.relapses | 10 |
| abstract_inverted_index.repeated | 41 |
| abstract_inverted_index.response | 120, 197, 206, 212 |
| abstract_inverted_index.resulted | 253 |
| abstract_inverted_index.standard | 105 |
| abstract_inverted_index.suitable | 34 |
| abstract_inverted_index.survival | 127, 131 |
| abstract_inverted_index.yielding | 215 |
| abstract_inverted_index.Consensus | 140 |
| abstract_inverted_index.Criteria. | 142 |
| abstract_inverted_index.Keywords: | 306 |
| abstract_inverted_index.Responses | 133 |
| abstract_inverted_index.abstract. | 317 |
| abstract_inverted_index.according | 137 |
| abstract_inverted_index.aplasia), | 64 |
| abstract_inverted_index.available | 77 |
| abstract_inverted_index.conflicts | 311 |
| abstract_inverted_index.diagnosis | 187 |
| abstract_inverted_index.expressed | 22 |
| abstract_inverted_index.following | 290 |
| abstract_inverted_index.interests | 313 |
| abstract_inverted_index.patients, | 223, 299 |
| abstract_inverted_index.pertinent | 314 |
| abstract_inverted_index.receiving | 91, 265 |
| abstract_inverted_index.relapsing | 39 |
| abstract_inverted_index.responded | 271 |
| abstract_inverted_index.response. | 227 |
| abstract_inverted_index.reviewed. | 99 |
| abstract_inverted_index.rituximab | 30, 93, 102, 150, 170, 266, 293 |
| abstract_inverted_index.treatment | 35, 124 |
| abstract_inverted_index.Resolution | 141 |
| abstract_inverted_index.especially | 65 |
| abstract_inverted_index.experience | 7 |
| abstract_inverted_index.objectives | 117 |
| abstract_inverted_index.predicting | 62 |
| abstract_inverted_index.categorized | 136 |
| abstract_inverted_index.countries). | 83 |
| abstract_inverted_index.moxetumomab | 71 |
| abstract_inverted_index.Single-agent | 29 |
| abstract_inverted_index.Thirty-three | 144 |
| abstract_inverted_index.cellularity, | 58 |
| abstract_inverted_index.infiltration | 61 |
| abstract_inverted_index.long-lasting | 63 |
| abstract_inverted_index.single-agent | 92 |
| abstract_inverted_index.time-to-next | 123 |
| abstract_inverted_index.vemurafenib) | 73 |
| abstract_inverted_index.Introduction: | 0 |
| abstract_inverted_index.institutional | 86 |
| abstract_inverted_index.Immunotherapy, | 307 |
| abstract_inverted_index.contraindicated | 50 |
| abstract_inverted_index.retrospectively | 98 |
| abstract_inverted_index.progression-free | 126 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 17 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.46000000834465027 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.2882583 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |